^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MUC4 expression

    i
    Other names: MUC4, Mucin 4, Cell Surface Associated, Pancreatic Adenocarcinoma Mucin, Mucin 4, Tracheobronchial, Ascites Sialoglycoprotein, Tracheobronchial Mucin, Testis Mucin, ASGP
    Entrez ID:
    4585
    Related biomarkers:
    Expression
    11ms
    Complex immunohistochemical and molecular study on 5 cases of ovarian juvenile granulosa cell tumors reveals a consistent alteration in the PI3K/AKT/mTOR signaling pathway. (PubMed, Diagn Pathol)
    The results of our study further support the hypothesis that the pathogenesis of JGCT may be driven by activation of the PIK3/AKT/mTOR pathway. These findings could potentially have future therapeutic implications, as treatment strategies targeting the PTEN/mTOR pathways are currently under investigation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • AR (Androgen receptor) • ARID1A (AT-rich interaction domain 1A) • TERT (Telomerase Reverse Transcriptase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • WT1 (WT1 Transcription Factor) • NKX2-1 (NK2 Homeobox 1) • CA9 (Carbonic anhydrase 9) • MUC4 (Mucin 4, Cell Surface Associated) • SALL4 (Spalt Like Transcription Factor 4) • CD99 (CD99 Molecule) • EP400 (E1A Binding Protein P400) • GATA3 (GATA binding protein 3) • NAPSA (Napsin A Aspartic Peptidase) • FOXL2 (Forkhead Box L2)
    |
    PD-L1 expression • HER-2 negative • HER-2 expression • PTEN expression • AKT1 mutation • TERT mutation • TP53 expression • MUC4 expression • CA9 expression
    12ms
    YAP1::KMT2A-rearranged sarcomas harbor a unique methylation profile and are distinct from sclerosing epithelioid fibrosarcoma and low-grade fibromyxoid sarcoma. (PubMed, Virchows Arch)
    DNA methylation analysis further showed that YAP1::KMT2A-rearranged sarcomas formed a distinct cluster, which was clearly separate from both conventional SEF and low-grade fibromyxoid sarcoma (LGFMS). These results suggest that YAP1::KMT2A-rearranged sarcomas likely represent a unique sarcoma subtype with propensity for aggressive behavior.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • EWSR1 (EWS RNA Binding Protein 1) • YAP1 (Yes associated protein 1) • FUS (FUS RNA Binding Protein) • MUC4 (Mucin 4, Cell Surface Associated) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
    |
    MLL rearrangement • MUC4 expression
    1year
    A molecular and immunohistochemical study of 37 cases of ovarian Sertoli-Leydig cell tumor. (PubMed, Virchows Arch)
    DICER1MUT and DICER1WT tumors showed different mRNA expression profiles. The FOXL2 mutation is less common in these tumors and is mutually exclusive with the DICER1 mutation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • TERT (Telomerase Reverse Transcriptase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • NOTCH2 (Notch 2) • CDK6 (Cyclin-dependent kinase 6) • CA9 (Carbonic anhydrase 9) • MUC4 (Mucin 4, Cell Surface Associated) • DICER1 (Dicer 1 Ribonuclease III) • CD99 (CD99 Molecule) • PRKCA (Protein Kinase C Alpha) • FOXL2 (Forkhead Box L2) • HNF1A (HNF1 Homeobox A)
    |
    PD-L1 negative • PTEN expression • TERT mutation • TERT promoter mutation • CTLA4 expression • MUC4 expression • CA9 expression • CDK6 expression
    1year
    Quantitative proteogenomic characterization in MUC1 and MUC4 in oral squamous cell carcinoma, oral potentially malignant disorders, and normal oral mucosa in carcinogenesis. (PubMed, Eur Arch Otorhinolaryngol)
    The study's results indicate that MUC1 & 4 individually are crucial for monitoring OSCC and OPMD pathogenesis as the former gives an idea of highly undifferentiated grades while the latter indicated more differentiated tumors and perhaps a better prognosis. Therefore, the two can be useful tumor markers for determining the severity and eliminating it in its early phases.
    Journal
    |
    MUC1 (Mucin 1) • MUC4 (Mucin 4, Cell Surface Associated)
    |
    MUC1 expression • MUC4 expression
    1year
    MUC17 is a potential new prognostic biomarker and promotes pancreatic cancer progression in obstructive jaundice. (PubMed, Oncology)
    Treatment of Capan-1 and AsPC-1 cells with BAs or with human serum obtained from PDAC + OJ patients enhanced the expression of MUC17, as well as the proliferative potential of the cells, whereas knockdown of MUC17 alone or in combination with MUC4 decreased BAs-induced carcinogenic processes. Our results demonstrated that MUC17 has a central role in bile-induced PC progression, and in addition to MUC4, this isoform also can be used as a novel prognostic biomarker.
    Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated) • MUC17 (Mucin 17)
    |
    MUC4 expression
    1year
    Molecular genetic analysis of colorectal carcinoma with an aggressive extraintestinal immunohistochemical phenotype. (PubMed, Sci Rep)
    CK7 + tumors showed intriguingly common (31.6%) BRAF V600E mutations corelating with poor prognosis, compared to the frequency described in the literature and databases. Further research on larger cohorts with a non-colorectal immunophenotype and high MUC4 expression is needed.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CLDN18 (Claudin 18) • SMAD4 (SMAD family member 4) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MUC4 (Mucin 4, Cell Surface Associated) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6) • SATB2 (SATB Homeobox 2)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • PIK3CA mutation • BRAF V600 • APC mutation • TP53 expression • MUC4 expression • CLDN1 positive • MUC5AC expression
    1year
    The intestinal mucin isoform landscape reveals region-specific biomarker panels for inflammatory bowel disease patient stratification. (PubMed, J Crohns Colitis)
    We unveiled region-specific mucin RNA isoform panels capturing the heterogeneity of the IBD patient population and showing great potential to indicate barrier function in IBD patients.
    Journal
    |
    MUC1 (Mucin 1) • MUC16 (Mucin 16, Cell Surface Associated) • MUC4 (Mucin 4, Cell Surface Associated) • MUC5AC (Mucin 5AC)
    |
    MUC4 expression
    1year
    Sclerosing Epithelioid Fibrosarcoma Harboring the EWSR1-CREB3L1 Gene Fusion: The Importance of Molecular Classification in Pediatric Sarcomas. (PubMed, J Pediatr Hematol Oncol)
    SEF is typically identified via genetic testing and recognition of the EWSR1-CREB3L1 gene fusion as well as MUC4 expression via immunohistochemistry. DNA methylation profiling, which has traditionally been used in brain tumors, can also efficiently identify this tumor, and we recommend expanding the use of this technology for difficult to classify pediatric sarcomas.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • MUC4 (Mucin 4, Cell Surface Associated) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
    |
    MUC4 expression
    1year
    Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites. (PubMed, Virchows Arch)
    This series further solidifies the notion that FET::CREB fusions are not limited to the triad of angiomatoid fibrous histiocytoma, clear cell sarcoma, and malignant gastrointestinal neuroectodermal tumor, but characterize an emerging family of potentially aggressive neoplasms occurring at both intra- and extra-abdominal sites. These tumors underscore the promiscuity of the FET::CREB fusions and highlight the pivotal role of phenotype-oriented classification of these neoplasms that share the same genotype, still featuring significant biological and behavioral distinctness.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • EWSR1 (EWS RNA Binding Protein 1) • CD34 (CD34 molecule) • SOX10 (SRY-Box 10) • FUS (FUS RNA Binding Protein) • MUC4 (Mucin 4, Cell Surface Associated) • ATF1 (Activating Transcription Factor 1) • CD99 (CD99 Molecule) • CREM (CAMP Responsive Element Modulator) • PAX8 (Paired box 8) • SYP (Synaptophysin)
    |
    MUC4 expression
    over1year
    Dietary vitamin B6 supplementation alleviates heat stress-induced intestinal barrier impairment by regulating the gut microbiota and metabolites in broilers. (PubMed, Poult Sci)
    A total of 83 differential metabolites associated with the amelioration of VB6 were identified, which were primarily enriched in glycerophospholipid metabolism, caffeine metabolism, and glutathione metabolism pathway. Collectively, VB6 may improve the growth performance and intestinal barrier function of heat-stressed broilers by regulating the ileal microbiota and metabolic homeostasis.
    Journal
    |
    IFNG (Interferon, gamma) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL18 (Interleukin 18) • MUC4 (Mucin 4, Cell Surface Associated) • MUC2 (Mucin 2) • TJP1 (Tight Junction Protein 1)
    |
    MUC4 expression
    over1year
    Single-cell Transcriptomics Reveals the Aggressive Landscape of High-Grade Serous Carcinoma and Therapeutic Targets in Tumor Microenvironment. (PubMed, Cancer Lett)
    Notably, similar to CAFs, immunosuppressive tumor-associated macrophage (TAM) subtypes underwent glycolipid metabolism reprogramming via PPARgamma regulation, promoting tumor metastasis. These findings shed light on the mechanisms driving the aggressiveness of HGSC, offering crucial insights for the development of novel therapeutic targets against this formidable cancer.
    Journal
    |
    S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • SDC1 (Syndecan 1) • MUC4 (Mucin 4, Cell Surface Associated) • CEACAM6 (CEA Cell Adhesion Molecule 6) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    MUC4 expression • S100A8 expression • S100A9 expression
    over1year
    Clinical significance of MUC-4 and associated proteins in Pancreatic and Periampullary Cancers. (PubMed, Pancreas)
    Differential expression of MUC-4 in pancreatic tumor tissues can help to differentiate PDAC from benign conditions.
    Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    MUC4 expression